

Title: Sex differences between females and males in antipsychotic medication efficacy and adverse effects in the treatment of schizophrenia

Short title: Sex differences and antipsychotics

Journal: CNS Drugs

Authors:

Megan Galbally^{1,2} ORCID [0000-0003-3909-1918](https://orcid.org/0000-0003-3909-1918)

Karen Wynter^{1,3} ORCID [0000-0003-4620-7691](https://orcid.org/0000-0003-4620-7691)

Dan Siskind^{4,5} ORCID [0000-0002-2072-9216](https://orcid.org/0000-0002-2072-9216)

Christoph U. Correll^{6,7,8,9} ORCID [0000-0002-7254-5646](https://orcid.org/0000-0002-7254-5646)

Korinne Northwood^{4,5} ORCID [0000-0001-6268-547X](https://orcid.org/0000-0001-6268-547X)

Susanna Every-Palmer¹⁰ ORCID [0000-0001-6455-9741](https://orcid.org/0000-0001-6455-9741)

Affiliations:

1. School of Clinical Sciences, Monash University, Australia
2. Health Futures Institute, Murdoch University, Australia
3. Faculty of Health, Deakin University, Australia
4. Faculty of Medicine, The University of Queensland, Brisbane, Australia
5. Metro South Addiction and Mental Health Hospital and Health Service, Brisbane, Australia
6. Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA
7. Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA
8. Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany
9. German Center for Mental Health (DZPG), partner site Berlin, Germany
10. Department of Psychological Medicine, University of Otago Wellington, New Zealand

Address Correspondence to: Professor Megan Galbally, megan.galbally@monash.edu

Supplementary Table 2: Dosage and dosage compliance by gender, within each treatment group

		Total n	Females Mean (SD)	Males Mean (SD)	p^1	d
Olanzapine	Clinician-rated compliance at final visit	238	2.58 (0.86)	2.61 (0.86)	0.575	0.036
	Proportion of capsules taken (based on pill count in returned bottle) at final visit	227	85.12 (24.17)	87.57 (23.34)	0.125	0.102
	Dose at final visit	244	20.63 (7.82)	21.35 (7.96)	0.478	0.026
	Average dose over phase	266	19.62 (6.69)	20.57 (6.53)	0.309	0.062
	Modal dose over phase	266	19.28 (7.56)	21.08 (7.28)	0.086	0.105
	Perphenazine	Clinician-rated compliance at final visit	190	2.54 (1.00)	2.62 (0.861)	0.945
Proportion of capsules taken (based on pill count in returned bottle) at final visit		182	82.57 (30.56)	87.46 (23)	0.865	0.013
Dose at final visit		194	21.55 (8.52)	23.12 (8.17)	0.251	0.082
Average dose over phase		210	20.26 (6.76)	21.45 (6.74)	0.254	0.079
Modal dose over phase		210	20.23 (7.98)	21.68 (7.81)	0.256	0.078
Quetiapine		Clinician-rated compliance at final visit	241	2.48 (0.918)	2.43 (1.06)	0.708
	Proportion of capsules taken (based on pill count in returned bottle) at final visit	224	84.65 (26.00)	81.59 (30.16)	0.615	-0.034
	Dose at final visit	240	563.64 (214.62)	601.08 (199.45)	0.285	0.073
	Average dose over phase	255	549.89 (169.77)	555.27 (162.66)	0.614	0.032
	Modal dose over phase	255	562.9 (199.37)	561.66 (190.74)	0.996	0.000
	Risperidone	Clinician-rated compliance at final visit	250	2.62 (0.876)	2.45 (0.991)	0.159

	Proportion of capsules taken (based on pill count in returned bottle) at final visit	237	86.72 (23.59)	83.49 (26.74)	0.861	0.011
	Dose at final visit	248	4.32 (1.49)	4.3 (1.51)	0.922	-0.006
	Average dose over phase	259	4.08 (1.22)	4.02 (1.22)	0.534	-0.039
	Modal dose over phase	259	4.04 (1.45)	4.06 (1.36)	1	0.000
Ziprasidone	Clinician-rated compliance at final visit	127	2.45 (1.06)	2.58 (0.85)	0.788	0.024
	Proportion of capsules taken (based on pill count in returned bottle) at final visit	118	83.61 (27.19)	85.65 (22.9)	0.495	-0.063
	Dose at final visit	127	4.32 (1.49)	4.3 (1.51)	0.899	-0.055
	Average dose over phase	138	108.89 (30.93)	117.61 (31.89)	0.155	0.121
	Modal dose over phase	138	112.56 (37.40)	118.53 (36.00)	0.441	0.066

SD: standard deviation

¹ *p*-values and effect sizes associated with Mann-Whitney U tests